Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
Cue Biopharma, Inc. (CUE), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on June 5, 2019. The filing reports the entry into a material definitive agreement to facilitate an equity offering.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the authorization to raise up to $30.0 million in aggregate gross proceeds through the sale of common stock.
Material Changes
On June 5, 2019, the Company entered into an At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated. Key terms include:
- Maximum Proceeds: Up to $30.0 million.
- Maximum Shares: Up to 4,156,000 shares of common stock (subject to adjustment for stock splits or similar transactions).
- Commission: Stifel is entitled to a commission of up to 3.0% of the aggregate gross proceeds.
- Method: Sales will be made "at-the-market" on or through the Nasdaq Capital Market, or in negotiated transactions with prior approval.
- Termination: The agreement terminates upon the sale of all shares or earlier termination by either party.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future performance. The primary risk disclosed relates to the potential dilution of existing shareholders resulting from the issuance of up to 4,156,000 new shares. The Company also agreed to customary indemnification and contribution rights for Stifel.
Investor Verification Checklist
- Verify the current share price to estimate the actual number of shares required to reach the $30.0 million cap.
- Review the prospectus supplement (File No. 333-229140) for detailed use of proceeds.
- Monitor subsequent filings for actual sales volume and proceeds generated under the Sales Agreement.
- Assess the impact of the 3.0% commission on net capital raised.